Sir, Non-fermenters (NF) are a heterogeneous group of aerobic, non-spore-forming gram-negative bacteria of the division Proteobacteria unable to ferment carbohydrate (e.g. glucose). There has been a steady increase in metallo β-lactamases (MBLs) producing strains of NF among clinical isolates (from wound swab, pus, sputum, blood, urine, tracheal aspirate, and various body fluids). MBLs are enzymes belonging to Ambler ' s Class B that can hydrolyze a wide variety of beta-lactam antibiotics. [1] Verona integron mediated MBL (VIM) and IMP (active on imipenem) are the most frequently acquired Class B enzymes. New Delhi metallo β-lactamases 1 (NDM1) has been found in multiple cases of India. [2] A total of hundred isolates of NF were obtained from various types of specimens. In this study, 20 out of 100 (20%) strains were resistant to imipenem. Out of 20 strains, 12 were (60%) found positive for MBL production by disc approximation test. A polymerase chain reaction (PCR) assay was performed to detect MBL encoding genes using specific primers. In this study, majority of the MBL production was because of blaNDM1 encoding gene (about ten of the isolates), and in other two cases, blaVIM1 and blaIMP1 were found. For patients infected with MBL producing NF, last resort compounds such as tigecycline and colistin offer the only means of treatment and in case of colistin, often at the cost of Letter to Editor serious side effects. Moreover tigecycline is currently not licensed for treatment of urinary tract infection. Also the higher cost precludes their use in routine condition. Thereby, this study is aimed at evaluating antimicrobial efficiency of sulbactomax (a novel fixed dose combination of ceftriaxone, sulbactum, and EDTA) in comparison with ceftriaxone, tigecycline, amoxicillin-clavulanic acid combination, piperacillin-tazobactum combination, colistin by antimicrobial susceptibility testing, time-kill curve analysis, and minimum inhibitory concentration (MIC) assay. Combination of ceftriaxone with sulbactum is a stable one and it enhances the spectrum of activity of ceftriaxone. Sulbactum demonstrates synergistic activity by reducing minimum inhibitory concentration for the combination. [3] Comparative in vivo study proved the efficacy and safety of the sulbactomax. [4] In house MBL producing NF were used for susceptibility study. Among the 12 MBL-positive isolates, 7 were Pseudomonas aeruginosa, 3 were Acinetobacter baumanii, and remaining 2 were A. lowfii. Ceftriaxone, sulbactomax, tigecycline, amoxicillin-clavulanic acid combination, piperacillin-tazobactum combination, and colistin used in this study were provided by Venus Remedis Limited, India. Susceptibility discs used in this study was procured from Hi media Lab Ltd. India. Susceptibility testing was done according to Kirby Bauer's disc diffusion following Clinical and Laboratory Standards Institute (CLSI) protocol. [5, 6] MIC was determined by agar dilution method according to CLSI guidelines. [7] The range of drug concentration of each antibiotic tested was 0.0625-250 mg/L. Results from our study proved that ceftriaxone has higher MIC value than sulbactomax, suggesting higher bactericidal activity in sulbactomax. In case of Pseudomonas aeruginosa, the range of MIC were found to be 4-16 mg/L against ceftriaxone, 1-2 mg/L against sulbactomax, which was distinctly much lower. In case of Acinetobacter spp. the range of MIC were found to be 16-64 mg/L against ceftriaxone, 2-4 mg/L against sulbactomax, which was also distinctly much lower. Findings from our study also demonstrated that sulbactomax has lower MIC value in comparison with other antimicrobials tested except in case of colistin and tigecycline having comparative MIC values. The susceptibility zone of NF was higher [ Figure 1 ] in cefoperazone sulbactum disc when compared with ceftriaxone, amoxicillin-clavulanic acid, piperacillin-tazobactum discs, and comparable with that of colistin and tigecycline. Muller-Hinton broth supplemented with calcium (25 mg/L) and magnesium (12.5 mg/L) was used for susceptibility testing and killing curve experiment. Time-kill curve analysis revealed bactericidal effect with 2× the MIC of sulbactomax and other antimicrobial tested achieved the earliest killing at 2 hours. In all organisms under study, time-kill curve analysis demonstrated maximum bacterial killing at 6 hours against each of the antibiotic tested. Sulbactomax demonstrated better bactericidal activity than comparison to ceftriaxone, amoxicillin-clavulanic acid, piperacillin-tazobactum, colistin. Tigecycline showed slightly better activity in comparison to sulbactomax. Our study demonstrated that ceftriaxone, amoxicillin-clavulanic acid combination, piperacillin-tazobactum combination have higher MIC values than sulbactomax. The MIC values of colistin and tigecycline were comparable with that of sulbactomax. Thus, it can be concluded that sulbactomax is a relatively cheap, safe novel antimicrobial combination that can be effective against MBL producer NF.
